GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » GC Cell Corp (XKRX:144510) » Definitions » Institutional Ownership

GC Cell (XKRX:144510) Institutional Ownership : 6.64% (As of Sep. 21, 2024)


View and export this data going back to 2016. Start your Free Trial

What is GC Cell Institutional Ownership?

Institutional ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, GC Cell's institutional ownership is 6.64%.

Insider Ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, GC Cell's Insider Ownership is 0.00%.

Float Percentage Of Total Shares Outstanding is the percentage of float shares relative to the total shares outstanding. As of today, GC Cell's Float Percentage Of Total Shares Outstanding is 0.00%.


GC Cell Institutional Ownership Historical Data

The historical data trend for GC Cell's Institutional Ownership can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

GC Cell Institutional Ownership Chart

GC Cell Historical Data

The historical data trend for GC Cell can be seen below:

2023-11-30 2023-12-31 2024-01-31 2024-02-29 2024-03-31 2024-04-30 2024-05-31 2024-06-30 2024-07-31 2024-08-31
Institutional Ownership 7.29 7.25 7.49 7.37 7.32 6.96 7.04 6.89 6.73 6.64

GC Cell Institutional Ownership Calculation

The percentage of shares that are owned by institutions out of the total shares outstanding.


GC Cell Business Description

Traded in Other Exchanges
N/A
Address
30 beongil to giheung-gu, Gyeonggi, 107 Lee Hyun, Yongin, KOR, 16 924
GC Cell Corp engages in the provision of anti-cancer immunotherapy. The company is developing an anticancer drug, which is in Phase II clinical trials; and stem cell treatment drugs. It also provides cell banking, sample inspection, clinical trial, and bio logistics services.

GC Cell Headlines

No Headlines